IMUX vs ABBV vs GILD vs BIIB vs INCY vs JPM vs KO

For growth investors, Incyte Corporation (INCY) is the stronger pick with 21.

2% revenue growth year-over-year, versus 1. 4% for Biogen Inc. (BIIB). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Immunic, Inc. (IMUX) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus AbbVie Inc. at 96. 1x. On forward P/E, Biogen Inc. is actually cheaper at 13. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus The Coca-Cola Company's 2. 26x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +123. 7%, compared to -90. 2% for Immunic, Inc. (IMUX). Over 10 years, the gap is even starker: JPM returned +465. 8% versus IMUX's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Immunic, Inc. 's 1. 80β — meaning IMUX is approximately -999% more volatile than KO relative to the S&P 500. On balance sheet safety, Incyte Corporation (INCY) carries a lower debt/equity ratio of 1% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Incyte Corporation (INCY) is pulling ahead at 21.

2% versus 1. 4% for Biogen Inc. (BIIB). On earnings-per-share growth, the picture is similar: Incyte Corporation grew EPS 41. 7% year-over-year, compared to -21. 1% for Biogen Inc.. Over a 3-year CAGR, INCY leads at 14. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Gilead Sciences, Inc.

(GILD) is the more profitable company, earning 28. 9% net margin versus 0. 0% for Immunic, Inc. — meaning it keeps 28. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GILD leads at 39. 7% versus 0. 0% for IMUX. At the gross margin level — before operating expenses — INCY leads at 91. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus The Coca-Cola Company's 2. 26x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Biogen Inc. (BIIB) trades at 13. 7x forward P/E versus 25. 3x for The Coca-Cola Company — 11. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GILD: 28. 3% to $161. 12.

In this comparison, ABBV (2.

9% yield), GILD (2. 5% yield), KO (2. 5% yield), JPM (1. 9% yield) pay a dividend. IMUX, BIIB, INCY do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Immunic, Inc. (IMUX) carries a higher beta of 1. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, IMUX: -99. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (IMUX (Healthcare) and ABBV (Healthcare) and GILD (Healthcare) and BIIB (Healthcare) and INCY (Healthcare) and JPM (Financial Services) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: IMUX is a small-cap quality compounder stock; ABBV is a large-cap quality compounder stock; GILD is a mid-cap quality compounder stock; BIIB is a mid-cap quality compounder stock; INCY is a mid-cap high-growth stock; JPM is a large-cap deep-value stock; KO is a large-cap quality compounder stock. ABBV, GILD, JPM, KO pay a dividend while IMUX, BIIB, INCY do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.